SCHEMBL24636892

SCHEMBL24636892

N/C(=N/O)c1ncc(Nc2ncc(-c3ccc(C(F)(F)F)cn3)o2)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.36
KIF11 P52732 1/20 0.35
TRPV1 Q8NER1 8/20 0.35
KDM4E B2RXH2 1/20 0.33
ALOX5 P09917 1/20 0.33
KMT2A Q03164 1/20 0.33
FLT1 P17948 2/20 0.33
KDR P35968 2/20 0.33
FLT4 P35916 1/20 0.33
VCP P55072 3/20 0.32
PRKAB2 O43741 1/20 0.32
LCK P06239 1/20 0.32
SRC P12931 1/20 0.32
FLT3 P36888 1/20 0.32
PRKAG1 P54619 1/20 0.32
PRKAA2 P54646 1/20 0.32
PRKAA1 Q13131 1/20 0.32
RPS6KA1 Q15418 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32
PRKAG3 Q9UGI9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22925786 1.00 NPSR1 (0.36) NPSR1KIF11TRPV1KDM4EALOX5
SCHEMBL28733719 1.00 NPSR1 (0.36) NPSR1KIF11TRPV1KDM4EALOX5
SCHEMBL22925928 0.87 KMT2A (0.40) NPSR1KIF11TRPV1KDM4EALOX5
SCHEMBL28733637 0.87 KMT2A (0.40) NPSR1KIF11TRPV1KDM4EALOX5
SCHEMBL22925592 0.87 TRPV1 (0.47) TRPV1ALOX5FLT1KDRFLT4
SCHEMBL28733675 0.87 TRPV1 (0.47) TRPV1ALOX5FLT1KDRFLT4
SCHEMBL22925596 0.85 NPSR1 (0.40) NPSR1KIF11TRPV1KDM4EALOX5
SCHEMBL28733840 0.85 NPSR1 (0.40) NPSR1KIF11TRPV1KDM4EALOX5
SCHEMBL22925757 0.85 NPSR1 (0.40) NPSR1KIF11TRPV1KDM4EALOX5
SCHEMBL29696330 0.85 NPSR1 (0.40) NPSR1KIF11TRPV1KDM4EALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB NPSR1 2967/4885KIF11 4192/4885TRPV1 4690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.